Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva)

NCT02157883 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

39

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Non Small Cell Lung Cancer
Advanced (Inoperable) Non Small Cell Lung Cancer

Interventions

PROCEDURE: Pharmacokinetic sampling
DRUG: AZD9291
DRUG: Itraconazole

Sponsor

AstraZeneca